查看文章

In response to emerging and re-emerging respiratory viral infections with high morbidity and mortality such as Coronavirus Disease 2019 (COVID-19), Middle East respiratory syndrome coronavirus (MERS-CoV), and influenza, early administration of broad-spectrum antivirals can facilitate pandemic control and improve patient outcomes. This provides empiric therapeutic options during the time-lag for developing specific drug/vaccine. AM80 (tamibarotene), an orally active retinoid, was demonstrated with broad-spectrum antiviral efficacy in a recent study. To maximise antiviral efficacy in respiratory tract, an inhalable powder formulation of AM80 was developed by spray freeze drying (SFD) technology with hydroxypropyl-β-cyclodextrin (HPβCD) as solubiliser. The formulation showed good aerosol performance, as evaluated by Next Generation Impactor, with a fine particle fraction of 65.1±7.9% and an emitted …